1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Xintela: Promising data for XSTEM in OA

  • Q&A with CEO Evy Lundgren-Åkerlund
  • Strong support for advancing XSTEM in OA
  • We reiterate our fair value of SEK 1.43 per share

Xintela recently announced promising interim data from its phase I/IIa study with XSTEM in knee osteoarthritis (OA). Data from 24 patients in all three dose levels have been analysed, 18 months after treatment. No serious safety or tolerability issues were recorded in the study and the company also received promising early efficacy data. Västra Hamnen contacted CEO Evy Lundgren-Åkerlund for a comment.

Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-03-28, kl 08:33
Källa MFN
Affiliate
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.